Engineered immune cells take aim at stubborn blood disorders
NCT ID NCT07441525
First seen Mar 03, 2026 · Last updated May 16, 2026 · Updated 9 times
Summary
This early-phase study tests a new treatment called RD06-05, which uses specially engineered immune cells (CAR-T cells) to target and destroy the faulty cells causing autoimmune blood diseases. The trial includes 27 adults with conditions like immune thrombocytopenia, autoimmune hemolytic anemia, or Evans syndrome. The goal is to see if the treatment is safe and can control the disease by reducing harmful immune attacks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science & Technology
RECRUITINGWuhan, Hubei, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.